{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:27:27Z","timestamp":1786505247981,"version":"build-2736575974"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.prp.2026.156613","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:41:19Z","timestamp":1783528879000},"page":"156613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Challenges in immunotherapy and targeted therapy era of advanced cutaneous melanoma: Toxicities, resistance, outcomes"],"prefix":"10.1016","volume":"286","author":[{"given":"Zhenyu","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeliang","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaituo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9897-2226","authenticated-orcid":false,"given":"Linlin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2026.156613_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.prp.2026.156613_bib2","article-title":"Characteristics, prognosis, and competing risk nomograms of cutaneous malignant melanoma: evidence for pigmentary disorders","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib3","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-Pd-1\/Pd-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156613_bib4","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","article-title":"Pembrolizumab Versus Ipilimumab for Advanced Melanoma: 10-Year Follow-up of the Phase Iii Keynote-006 Study","volume":"35","author":"Long","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1200\/JCO.21.02549","article-title":"Checkmate-067: raising the bar for the next decade in oncology","volume":"40","author":"Weiss","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/imt-2018-0208","article-title":"Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of braf-mutant advanced melanoma: a matching-adjusted indirect comparison","volume":"11","author":"Atkins","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.prp.2026.156613_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/14740338.2018.1390562","article-title":"The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma","volume":"17","author":"Knispel","year":"2018","journal-title":"Expert. Opin. Drug. Saf."},{"key":"10.1016\/j.prp.2026.156613_bib8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with braf(V600)-mutant melanoma brain metastases (Combi-Mb): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156613_bib10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1186\/s12885-018-4788-5","article-title":"Early cost-effectiveness of tumor infiltrating lymphocytes (Til) for second line treatment in advanced melanoma: a model-based economic evaluation","volume":"18","author":"Retel","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2026.156613_bib11","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prp.2026.156613_bib14","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to Pd-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156613_bib15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","article-title":"Genomic and transcriptomic features of response to anti-Pd-1 therapy in metastatic melanoma","volume":"168","author":"Hugo","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156613_bib16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ccell.2025.01.009","article-title":"Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma","volume":"43","author":"Schiantarelli","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156613_bib17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","article-title":"Clinical acquired resistance to raf inhibitor combinations in braf-mutant colorectal cancer through mapk pathway alterations","volume":"5","author":"Ahronian","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156613_bib18","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.prp.2026.156613_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-pd-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.prp.2026.156613_bib20","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-Pd-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.prp.2026.156613_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102788","article-title":"Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma","volume":"129","author":"De Simoni","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.prp.2026.156613_bib22","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.prp.2026.156613_bib23","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaad.2012.11.037","article-title":"Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012","volume":"68","author":"Karia","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.prp.2026.156613_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.sder.2011.02.002","article-title":"Update on the management of high-risk squamous cell carcinoma","volume":"30","author":"LeBoeuf","year":"2011","journal-title":"Semin. Cutan. Med. Surg."},{"key":"10.1016\/j.prp.2026.156613_bib25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2105\/AJPH.2020.305567","article-title":"New Systematic therapies and trends in cutaneous melanoma deaths among us whites, 1986-2016","volume":"110","author":"Berk-Krauss","year":"2020","journal-title":"Am. J. Public. Health"},{"key":"10.1016\/j.prp.2026.156613_bib26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ijc.27616","article-title":"International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk?","volume":"132","author":"Erdmann","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2026.156613_bib27","article-title":"The rapid rise in cutaneous melanoma diagnoses","volume":"384","author":"Goldsmith","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156613_bib28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1056\/NEJMsb2019760","article-title":"The rapid rise in cutaneous melanoma diagnoses","volume":"384","author":"Welch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156613_bib29","article-title":"The rapid rise in cutaneous melanoma diagnoses","volume":"384","author":"Grossman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156613_bib30","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/jid.2010.354","article-title":"Gender differences in melanoma survival: female patients have a decreased risk of metastasis","volume":"131","author":"Joosse","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.prp.2026.156613_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2018.08.001","article-title":"Cutaneous squamous cell carcinoma","volume":"33","author":"Waldman","year":"2019","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"10.1016\/j.prp.2026.156613_bib33","first-page":"205","article-title":"Economic burden of skin cancer treatment in the USA: an analysis of the medical expenditure panel survey data, 2012-2018","volume":"34","author":"Kao","year":"2023","journal-title":"Cancer Causes Control."},{"key":"10.1016\/j.prp.2026.156613_bib34","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2023.09.049","article-title":"Gender differences in pediatric and adolescent melanoma: a retrospective analysis of 4645 cases","volume":"90","author":"Fernandez","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.prp.2026.156613_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/pcmr.12418","article-title":"Germline determinants of clinical outcome of cutaneous melanoma","volume":"29","author":"Vogelsang","year":"2016","journal-title":"Pigment. Cell. Melanoma Res."},{"key":"10.1016\/j.prp.2026.156613_bib36","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/bjd\/ljaf251","article-title":"The rise of new targets in melanoma","volume":"193","author":"Bai","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.prp.2026.156613_bib37","doi-asserted-by":"crossref","unstructured":"International Trends in the Incidence of Cutaneous Squamous Cell Carcinoma and Melanoma. Br J Dermatol. 2024;190:e40.","DOI":"10.1093\/bjd\/ljae072"},{"key":"10.1016\/j.prp.2026.156613_bib38","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.prp.2026.156613_bib39","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156613_bib40","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40264-020-00979-4","article-title":"Ipilimumab-induced enterocolitis: a systematic review and meta-analysis","volume":"43","author":"Witges","year":"2020","journal-title":"Drug. Saf."},{"key":"10.1016\/j.prp.2026.156613_bib41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.prp.2026.156613_bib42","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2014.57.3535","article-title":"Combined Braf (Dabrafenib) and mek inhibition (Trametinib) in patients with Brafv600-mutant melanoma experiencing progression with single-agent braf inhibitor","volume":"32","author":"Johnson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib43","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with braf V600e mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156613_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(22)00687-8","article-title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in Braf(V600) mutation-positive advanced melanoma (Imspire150): second interim analysis of a multicentre, randomised, phase 3 study","volume":"24","author":"Ascierto","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib45","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced braf(v600) mutation-positive melanoma (Imspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2026.156613_bib46","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-Pd-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (Irprc)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib47","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib48","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced braf-mutant melanoma: the dreamseq trial-ecog-acrin Ea6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CMR.0000000000000542","article-title":"Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma","volume":"29","author":"Stera","year":"2019","journal-title":"Melanoma Res."},{"key":"10.1016\/j.prp.2026.156613_bib50","article-title":"The effect of hypoxia-induced exosomes on anti-tumor immunity and its implication for immunotherapy","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156613_bib51","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156613_bib52","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156613_bib53","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ccc.2013.03.004","article-title":"Fulminant myocarditis","volume":"29","author":"Ginsberg","year":"2013","journal-title":"Crit. Care Clin."},{"key":"10.1016\/j.prp.2026.156613_bib54","article-title":"Cardiovascular-related hospital visits amongst oncology patients receiving immune checkpoint inhibitors: a population-based cohort study","author":"Dai","year":"2025","journal-title":"J. Cardiol."},{"key":"10.1016\/j.prp.2026.156613_bib55","doi-asserted-by":"crossref","first-page":"912","DOI":"10.21037\/tlcr-2025-150","article-title":"Analysis of baseline interstitial lung abnormality on the risk of checkpoint inhibitor-related pneumonitis and survival in advanced non-small cell lung cancer patients treated with first-line Pd-1\/Pd-L1 inhibitors","volume":"14","author":"Li","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.prp.2026.156613_bib56","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"Pd-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156613_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.678409","article-title":"Hyperprogressive disease in cancers treated with immune checkpoint inhibitors","volume":"12","author":"Shen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.prp.2026.156613_bib58","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-Pd-1 monotherapy and anti-Pd-1\/Anti-Ctla-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156613_bib59","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156613_bib60","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cell.2018.12.034","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"176","author":"Sade-Feldman","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156613_bib61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-Pd-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156613_bib62","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The Commensal microbiome is associated with anti-pd-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.prp.2026.156613_bib63","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.prp.2026.156613_bib64","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00262-020-02716-3","article-title":"Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma","volume":"70","author":"Schuiveling","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.prp.2026.156613_bib65","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1634\/theoncologist.2014-0429","article-title":"Adjusting for the confounding effects of treatment switching-the break-3 trial: dabrafenib versus dacarbazine","volume":"20","author":"Latimer","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.prp.2026.156613_bib66","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40265-016-0562-7","article-title":"Cobimetinib plus vemurafenib: a review in braf (v600) mutation-positive unresectable or metastatic melanoma","volume":"76","author":"Keating","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.prp.2026.156613_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114073","article-title":"Columbus 7-year update: a randomized, open-label, phase iii trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with braf v600e\/k-mutant melanoma","volume":"204","author":"Schadendorf","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2026.156613_bib68","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1078-0432.CCR-22-2581","article-title":"Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with braf-mutant melanoma brain metastases","volume":"29","author":"Wilmott","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156613_bib69","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/s12967-023-04391-1","volume":"21","author":"Dummer","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.prp.2026.156613_bib70","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nature23291","article-title":"Tumours with class 3 braf mutants are sensitive to the inhibition of activated ras","volume":"548","author":"Yao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156613_bib71","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-Raf(V600e) inhibition by rtk or n-ras upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156613_bib72","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"Cot drives resistance to raf inhibition through map kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156613_bib73","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to Braf(V600e) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156613_bib74","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","article-title":"Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress","volume":"33","author":"Tsoi","year":"2018","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156613_bib75","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","article-title":"Toward minimal residual disease-directed therapy in melanoma","volume":"174","author":"Rambow","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156613_bib76","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.11414","article-title":"Reproducibility project: cancer b., registered report: cot drives resistance to raf inhibition through map kinase pathway reactivation","volume":"5","author":"Sharma","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.prp.2026.156613_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102238","article-title":"Nras mutant melanoma: towards better therapies","volume":"99","author":"Randic","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.prp.2026.156613_bib78","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.7150\/thno.36218","article-title":"The \"art\" of epigenetics in melanoma: from histone \"alterations, to resistance and therapies\"","volume":"10","author":"Strub","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.prp.2026.156613_bib79","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156613_bib80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156613_bib81","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156613_bib82","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41571-023-00848-w","article-title":"Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma","volume":"21","author":"Klobuch","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib83","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","article-title":"Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future","volume":"29","author":"Betof Warner","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156613_bib84","doi-asserted-by":"crossref","first-page":"600","DOI":"10.14423\/SMJ.0000000000001166","article-title":"Immune checkpoint inhibitor-related pulmonary toxicity: focus on nivolumab","volume":"113","author":"Bukamur","year":"2020","journal-title":"South. Med. J."},{"key":"10.1016\/j.prp.2026.156613_bib85","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/OTT.S57335","article-title":"Ipilimumab in the treatment of metastatic melanoma: management of adverse events","volume":"7","author":"Della Vittoria Scarpati","year":"2014","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.prp.2026.156613_bib86","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/157489208784638767","article-title":"Anti-Ctla4 monoclonal antibody ipilimumab in the treatment of metastatic melanoma: recent findings","volume":"3","author":"Lens","year":"2008","journal-title":"Recent. Pat. Anticancer. Drug. Discov."},{"key":"10.1016\/j.prp.2026.156613_bib87","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib88","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156613_bib89","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156613_bib90","doi-asserted-by":"crossref","first-page":"331","DOI":"10.14740\/wjon2613","article-title":"Efficacy of infliximab versus vedolizumab in the management of immune checkpoint inhibitor-induced colitis: a systematic review and meta-analysis","volume":"16","author":"Shambhavi","year":"2025","journal-title":"World J. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib91","first-page":"567","article-title":"Severe and refractory gastrointestinal toxicity due to immune checkpoint inhibitors: clinical experience in a tertiary referral hospital","volume":"115","author":"Cespedes Martinez","year":"2023","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"10.1016\/j.prp.2026.156613_bib92","article-title":"A Case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy","volume":"100","author":"Hirasawa","year":"2021","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.prp.2026.156613_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013038","article-title":"Infliximab Is a safe and effective treatment in steroid-refractory immune-related hepatitis","volume":"13","author":"Oliva","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156613_bib94","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.22.02072","article-title":"Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1\/programmed Death Ligand 1 Therapy: Results from the Phase I\/Iia Relativity-020 Trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib95","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156613_bib96","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1007\/s12311-024-01727-5","article-title":"Immune checkpoint inhibitor-related cerebellar toxicity: clinical features and comparison with paraneoplastic cerebellar ataxia","volume":"23","author":"Dentoni","year":"2024","journal-title":"Cerebellum"},{"key":"10.1016\/j.prp.2026.156613_bib97","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/jac\/dkaf231","article-title":"Trimethoprim\/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (hlh): a literature review and disproportionality analysis using individual case safety reports from faers","volume":"80","author":"Lau","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.prp.2026.156613_bib98","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2025.02.001","article-title":"Fak inhibition combined with the raf-mek clamp avutometinib overcomes resistance to targeted and immune therapies in braf v600e melanoma","volume":"43","author":"Lubrano","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156613_bib99","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-319-91442-8_6","article-title":"Vemurafenib","volume":"211","author":"Garbe","year":"2018","journal-title":"Recent. Results Cancer Res."},{"key":"10.1016\/j.prp.2026.156613_bib100","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined braf, egfr, and mek inhibition in patients with braf(v600e)-mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156613_bib101","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib102","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated braf-mutated metastatic melanoma (secombit): a randomized, three-arm, open-label phase ii trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib103","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cytogfr.2024.08.001","article-title":"Targeting Pd-1\/Pd-L1 in tumor immunotherapy: mechanisms and interactions with host growth regulatory pathways","volume":"79","author":"Shen","year":"2024","journal-title":"Cytokine Growth Factor. Rev."},{"key":"10.1016\/j.prp.2026.156613_bib104","article-title":"Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156613_bib105","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.18.02258","article-title":"Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from calgb\/swog 80405 (alliance)","volume":"37","author":"Lenz","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib106","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00105-014-3567-8","article-title":"Abscopal effect in the treatment of malignant melanoma","volume":"66","author":"Thallinger","year":"2015","journal-title":"Hautarzt"},{"key":"10.1016\/j.prp.2026.156613_bib107","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41420-024-02171-4","article-title":"Blockade of Cd73 potentiates radiotherapy antitumor immunity and abscopal effects via sting pathway","volume":"10","author":"An","year":"2024","journal-title":"Cell. Death Discov."},{"key":"10.1016\/j.prp.2026.156613_bib108","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818798792","article-title":"Srs in combination with ipilimumab: a promising new dimension for treating melanoma brain metastases","volume":"17","author":"Khan","year":"2018","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.prp.2026.156613_bib109","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11060-025-05120-y","article-title":"Management outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockade","volume":"175","author":"Seidel","year":"2025","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.prp.2026.156613_bib110","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/cncr.34227","article-title":"Relatlimab plus nivolumab beneficial for previously untreated metastatic or unresectable melanoma","volume":"128","author":"O\u2032Rourke","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2026.156613_bib111","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1200\/JCO.24.01124","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from relativity-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156613_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115547","article-title":"Nivolumab plus relatlimab in advanced melanoma: relativity-047 4-year update","volume":"225","author":"Lipson","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2026.156613_bib113","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of pd-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.prp.2026.156613_bib114","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","article-title":"Fecal microbiota transplantation plus anti-pd-1 immunotherapy in advanced melanoma: a phase I trial","volume":"29","author":"Routy","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.prp.2026.156613_bib115","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0148607108331176","article-title":"Comment on: probiotic prophylaxis in predicted severe acute pancreatitis: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"McClave","year":"2009","journal-title":"JPEN J. Parenter. Enter. Nutr."},{"key":"10.1016\/j.prp.2026.156613_bib116","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(08)60207-X","article-title":"Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial","volume":"371","author":"Besselink","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2026.156613_bib117","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.06.2011.4412","article-title":"Saccharomyces boulardii fungemia caused by treatment with a probioticum","volume":"2012","author":"Thygesen","year":"2012","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.prp.2026.156613_bib118","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E. Coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156613_bib119","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.18632\/oncotarget.5788","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"Gray","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2026.156613_bib120","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40257-024-00852-5","article-title":"Rapidly evolving pre- and post-surgical systemic treatment of melanoma","volume":"25","author":"Augustin","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.prp.2026.156613_bib121","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.3233\/TUB-220044","article-title":"Circulating Tumor DNA (Ctdna) as a biomarker for lung cancer: early detection, monitoring and therapy prediction","volume":"46","author":"Duffy","year":"2024","journal-title":"Tumour Biol."},{"key":"10.1016\/j.prp.2026.156613_bib122","doi-asserted-by":"crossref","first-page":"25265","DOI":"10.18632\/oncotarget.25404","article-title":"Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-Pd1 immunotherapy","volume":"9","author":"Herbreteau","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2026.156613_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1509968","article-title":"The role of circulating tumor dna in melanomas of the uveal tract","volume":"15","author":"Zameer","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156613_bib124","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102914","article-title":"Circulating tumor DNA testing opens new perspectives in melanoma management","volume":"12","author":"Sacco","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2026.156613_bib125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041106","article-title":"Immunotherapy in melanoma: recent advances and future directions","volume":"15","author":"Knight","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2026.156613_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216633","article-title":"Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma","volume":"586","author":"Zhang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2026.156613_bib127","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11912-021-01120-z","article-title":"Immunotherapy for non-melanoma skin cancer","volume":"23","author":"Shalhout","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.prp.2026.156613_bib128","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00262-014-1647-3","article-title":"Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma","volume":"64","author":"Ascierto","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.prp.2026.156613_bib129","article-title":"Advances in immunotherapy and targeted therapy of malignant melanoma","volume":"13","author":"Wang","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.prp.2026.156613_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102960","article-title":"When to stop immunotherapy for advanced melanoma: the emulated target trials","volume":"78","author":"Amiot","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"42","key":"10.1016\/j.prp.2026.156613_bib131","first-page":"1","article-title":"Double trouble: immunotherapy doublets in melanoma-approved and novel combinations to optimize treatment in advanced melanoma","author":"Dimitriou","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:41:25Z","timestamp":1786502485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826002669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":131,"alternative-id":["S0344033826002669"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156613","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in immunotherapy and targeted therapy era of advanced cutaneous melanoma: Toxicities, resistance, outcomes","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156613"}}